Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC
Clinical trial NCT05485896 · COMPLETED
Trial details
- NCT number
- NCT05485896
- Sponsor
- Tianjin Medical University Second Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-01
- Primary completion
- 2023-12-31
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.